Gentabac80 mg/2 ml

Gentabac 80 mg/2 ml is an aminoglycoside antibiotic available in Bangladesh as an injectable formulation (for systemic infections) and as topical/ophthalmic preparations (eye drops, eye ointment, and ear drops). Its uses differ significantly by formulation and route.

Injectable (Systemic) Use - FDA-Approved / Established

• Serious infections caused by susceptible strains of gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Citrobacter, and indole-positive and indole-negative Proteus species
• Septicemia (bloodstream infection)
• Complicated and serious urinary tract infections
• Bacterial meningitis (often as part of combination therapy)
• Serious lower respiratory tract infections
• Intra-abdominal infections, including peritonitis
• Serious skin, bone, and soft-tissue infections, and infected burns

Combination therapy: Gentabac 80 mg/2 ml is frequently used together with a beta-lactam antibiotic (e.g., penicillin or ampicillin) for synergistic coverage against certain gram-positive organisms, such as in Staphylococcus aureus infections and streptococcal/enterococcal endocarditis. It should not be physically mixed in the same syringe or IV bag with beta-lactam antibiotics (see Drug Interactions).

Neonatal sepsis: Gentabac 80 mg/2 ml is a guideline-supported component of empiric combination therapy for suspected early-onset neonatal sepsis.

Topical/Ophthalmic Use - Established

• Superficial bacterial infections of the eye caused by susceptible organisms, including conjunctivitis, blepharitis, blepharoconjunctivitis, keratitis, and corneal ulcers
• Bacterial infections of the outer ear (otitis externa)
• Susceptible superficial skin infections (topical cream/ointment forms)

Formulation choice should be guided by a physician based on the site and severity of infection; ophthalmic/topical forms are not effective for, and must never be substituted for, systemic infections.

Each mL of Gentabac 80 mg/2 ml injectable solution typically contains Gentabac 80 mg/2 ml equivalent to 40 mg (or 10 mg/mL in pediatric strength) of gentamicin base, as available in Bangladesh. Ophthalmic solution typically contains 0.3% Gentabac 80 mg/2 ml (equivalent to 3 mg gentamicin base per mL), and ophthalmic/topical ointment or cream typically contains 0.1% or 0.3% Gentabac 80 mg/2 ml. Exact strength and excipients vary by manufacturer and brand; consult the specific product packaging.

Gentabac 80 mg/2 ml is a broad-spectrum aminoglycoside antibiotic derived from Micromonospora purpurea. It works by binding irreversibly to the bacterial 30S ribosomal subunit, disrupting protein synthesis and causing a bactericidal (killing) effect against a wide range of aerobic gram-negative bacteria and, in combination with cell-wall-active agents, certain gram-positive organisms. Because it is poorly absorbed from the gastrointestinal tract, systemic effect requires injection (intramuscular or intravenous); topical and ophthalmic forms act locally on the skin, eye, or ear. Gentabac 80 mg/2 ml has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small, which is why systemic use requires careful dosing and monitoring.

Gentabac 80 mg/2 ml belongs to the aminoglycoside class of antibiotics.

Gentabac 80 mg/2 ml exerts its antibacterial action by irreversibly binding to specific proteins on the 30S ribosomal subunit of susceptible bacteria, interfering with the initiation complex of protein synthesis and causing misreading of the genetic code, which leads to a non-functional or toxic protein and ultimately bacterial cell death. This mechanism is bactericidal and is enhanced under aerobic conditions, which is why Gentabac 80 mg/2 ml has limited activity against anaerobic bacteria.

Pharmacokinetics: After intramuscular injection, Gentabac 80 mg/2 ml is rapidly and almost completely absorbed, with peak serum concentrations occurring within 30-90 minutes. It is not significantly metabolized and is eliminated almost entirely unchanged by glomerular filtration in the kidneys, with a serum half-life of approximately 2-3 hours in patients with normal renal function; this half-life is markedly prolonged in renal impairment. Gentabac 80 mg/2 ml does not cross the blood-brain barrier well in the absence of meningeal inflammation and has poor oral bioavailability, which is why systemic infections require parenteral (injectable) administration.

Injectable form: Administered by intramuscular injection or by slow intravenous infusion (typically diluted in 50-200 mL of normal saline or dextrose solution and infused over 30-60 minutes), only by or under the direction of a qualified healthcare professional. Never self-administer the injectable form.

Ophthalmic drops/ointment: Wash hands before use; avoid touching the applicator tip to the eye or any surface; tilt the head back and instill into the lower eyelid pouch; apply gentle pressure to the inner corner of the eye for about a minute after drops to reduce systemic absorption; do not wear contact lenses during treatment unless directed otherwise.

Ear drops: Warm the bottle slightly in the hand before use; lie with the affected ear upward, instill drops, and remain in position for a few minutes.

Topical cream/ointment: Clean and dry the affected area before applying a thin layer; wash hands after application unless the hands are the treated area.

Gentabac 80 mg/2 ml has several clinically significant drug interactions, mainly relevant to systemic (injectable) use:

• Other nephrotoxic or ototoxic drugs (e.g., other aminoglycosides, vancomycin, amphotericin B, cisplatin, potent loop diuretics such as furosemide or ethacrynic acid): concurrent or sequential use with Gentabac 80 mg/2 ml increases the risk of kidney damage and hearing/balance damage and should be avoided unless clearly necessary and closely monitored.
• Neuromuscular blocking agents and general anesthetics: Gentabac 80 mg/2 ml can potentiate neuromuscular blockade, increasing the risk of prolonged muscle weakness or respiratory depression, particularly in patients with myasthenia gravis or other neuromuscular disorders.
• Beta-lactam antibiotics (e.g., penicillins) in vitro: while often used together intentionally for synergy, Gentabac 80 mg/2 ml can be chemically inactivated if physically mixed in the same IV solution or syringe as a beta-lactam antibiotic; the two must be administered separately, at different sites or times.
• Other nephrotoxic agents such as NSAIDs and certain antivirals may further increase the risk of kidney injury when combined with Gentabac 80 mg/2 ml.

Always inform the physician of all medicines, supplements, and herbal products being used before starting Gentabac 80 mg/2 ml.

Side effects of Gentabac 80 mg/2 ml depend substantially on the route of administration.

Systemic (Injectable) Use

• Nephrotoxicity: kidney damage, which is usually reversible if detected early and the drug is discontinued or the dose adjusted; risk increases with higher doses, longer duration, dehydration, pre-existing renal impairment, and concurrent nephrotoxic drugs.
• Ototoxicity: damage to hearing (cochlear toxicity - tinnitus, hearing loss) and/or balance (vestibular toxicity - dizziness, vertigo, unsteadiness); this can be irreversible and may not appear until after treatment has ended.
• Neuromuscular blockade: muscle weakness or, rarely, respiratory paralysis, especially with rapid infusion, high doses, or in patients with neuromuscular disorders.
• Other reported effects: nausea, vomiting, rash, fever, headache, injection-site pain, and laboratory abnormalities (elevated liver enzymes, low magnesium/potassium/calcium).

Ophthalmic/Topical Use

• Local burning, stinging, or itching upon instillation
• Conjunctival redness (hyperemia) or irritation
• Rarely, allergic/hypersensitivity skin reactions or delayed corneal healing with prolonged use

Gentabac 80 mg/2 ml should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Gentabac 80 mg/2 ml crosses the placenta, and aminoglycosides as a class have been associated with reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy; although similar data specifically for Gentabac 80 mg/2 ml are limited, this class-wide fetal ototoxicity risk warrants caution, and use in pregnancy should only occur under close physician supervision, generally reserved for serious or life-threatening maternal infections where alternatives are not suitable.

Gentabac 80 mg/2 ml is excreted in breast milk in small amounts. Because of the potential for adverse effects in a nursing infant, a physician should be consulted to weigh the benefits of breastfeeding against the potential risk, and alternative feeding or alternative antibiotics may be considered where appropriate.

Gentabac 80 mg/2 ml, when used systemically, carries a narrow therapeutic index and requires close medical supervision:

• Nephrotoxicity and ototoxicity risk: patients should be adequately hydrated, and renal function (serum creatinine/BUN) and, where possible, serum gentamicin concentrations should be monitored during therapy, particularly in patients with pre-existing renal impairment, the elderly, neonates, or those on prolonged therapy. Report any hearing changes, ringing in the ears, dizziness, or decreased urination promptly.
• Neuromuscular blockade: use with caution in patients with myasthenia gravis, Parkinson's disease, or other conditions involving muscle weakness, as Gentabac 80 mg/2 ml can worsen neuromuscular transmission.
• Antibiotic stewardship: take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Inappropriate use contributes to antibiotic resistance and increases toxicity risk without added benefit.
• Superinfection: prolonged use, especially of topical/ophthalmic forms, may result in overgrowth of non-susceptible organisms, including fungi.
• Cross-sensitivity may occur among different aminoglycoside antibiotics.

Overdose or excessive dosing of Gentabac 80 mg/2 ml (systemic use) increases the risk of severe nephrotoxicity, ototoxicity, and neuromuscular blockade (which can progress to respiratory paralysis). If an overdose of Gentabac 80 mg/2 ml is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Hemodialysis may be used by medical professionals to help remove Gentabac 80 mg/2 ml from the blood in cases of significant overdose or in patients with renal failure; calcium salts may be used under medical supervision to help reverse severe neuromuscular blockade. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze injectable solutions. Discard any unused portion of opened multi-dose vials or opened ophthalmic/topical preparations according to the product label or after the recommended period of use.

Renal impairment: requires dose and/or dosing interval adjustment and closer monitoring, as Gentabac 80 mg/2 ml is eliminated by the kidneys and accumulates in renal impairment, increasing toxicity risk (see Dosage and Administration and Precautions).

Hepatic impairment: no specific dose adjustment is established, as Gentabac 80 mg/2 ml is not significantly metabolized by the liver; however, general caution and monitoring are still advised in critically ill patients.

Elderly patients: may have reduced renal function even with normal serum creatinine; dose adjustment and close monitoring for nephrotoxicity and ototoxicity are recommended.

Obese patients: dosing is generally based on an adjusted or ideal body weight, as determined by the physician, to avoid overdosing.

Duration of Gentabac 80 mg/2 ml systemic therapy is individualized by the treating physician based on the infection and clinical response, typically 7-10 days; some serious infections (e.g., endocarditis) may require longer combination therapy under specialist supervision. Ophthalmic/topical use is typically continued for 7-10 days or as directed, and treatment should not be stopped early or extended beyond the prescribed course without medical advice, to reduce the risk of toxicity and antibiotic resistance.

Aminoglycoside antibiotics.

Gentabac 80 mg/2 ml binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, disrupting protein synthesis by causing misreading of mRNA codons, which results in the production of non-functional proteins and ultimately bactericidal (bacteria-killing) activity, primarily against aerobic gram-negative organisms.

The safety and efficacy of systemic Gentabac 80 mg/2 ml in pediatric patients, including neonates and infants, have been established for serious infections, but dosing must be individualized by weight, gestational/postnatal age, and renal function, with close monitoring of serum drug levels, renal function, and hearing where feasible, given the increased risk of toxicity in this population. Ophthalmic and topical Gentabac 80 mg/2 ml may be used in children as directed by a physician; safety and efficacy of some specific pediatric age ranges for topical/ophthalmic forms should be confirmed with the prescribing physician, as labeling can vary by product and manufacturer.